A multicenter randomized phase III trial comparing Avelumab vs genomic driven chemotherapy and genomic driven chemotherapy vs standard chemotherapy according to investigator's choice in elderly untreated Non-small cell lung cancer
Latest Information Update: 24 Feb 2020
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms EPIC
- 01 Oct 2019 Enrollment completion is expected by the end of 2022, according to the Trial design presented at the 44th European Society for Medical Oncology Congress.
- 01 Oct 2019 Trial design presented at the 44th European Society for Medical Oncology Congress.
- 01 Oct 2019 On June 2018 the protocol was amended with the introduction of a new study arm (Avelumab), aiming to clarify the best strategy in elderly untreated NSCLC patients, according to the Trial design presented at the 44th European Society for Medical Oncology Congress.